Fda Adverse Event Reporting
Fda Adverse Event Reporting - Related Videos
10:29
The NeuroStar TMS Device: Conducting the FDA Approved Protocol for Treatment of Depression
0 Views •
Cited by 83 •
2010
In this article, we examine the methodology and considerations relevant to the FDA approved depression treatment protocol using the Neuronetics NeuroStar TMS device.
10:03
Generation of Recombinant Arenavirus for Vaccine Development in FDA-Approved Vero Cells
0 Views •
Cited by 24 •
2013
Rescue of recombinant arenaviruses from cloned cDNAs, an approach referred to as reverse genetics, allows researchers to investigate the role of specific viral gene products, as well as the contribution of their different specific domains and residues, to many different aspects of the biology of arenavirus. Likewise, reverse genetics techniques in FDA-approved cell lines (Vero) for vaccine development provides novel possibilities for the generation of effective and safe vaccines to combat human...
05:05
Labeling Stem Cells with Ferumoxytol, an FDA-Approved Iron Oxide Nanoparticle
0 Views •
Cited by 95 •
2011
We describe a technique for labeling and tracking stem cells with FDA-approved, superparamagnetic iron oxide (SPIO), ferumoxytol (Feraheme). This cellular imaging technique that utilizes magnetic resonance (MR) imaging for visualization, is readily accessible for long-term monitoring and diagnosis of successful or unsuccessful stem cell engraftments in patients.
01:26
FDA Approved Drugs: Changes to Approved Drugs
0 Views •
2025
Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
09:00
Live Cell Imaging of Early Autophagy Events: Omegasomes and Beyond
0 Views •
Cited by 13 •
2013
Time-lapse microscopy of fluorescently labeled autophagy markers allows monitoring of the dynamic autophagy response with high temporal resolution. Using specific autophagy and organelle markers in a combination of 3 different colors, we can follow the contribution of a protein to autophagosome formation in a robust spatial and temporal context.
FAQs
An individual report describes a suspected association, not a confirmed cause-and-effect relationship. Reports may be incomplete, and the event can require comparison with clinical studies and other evidence before its meaning becomes clearer. Treating the report as an initial safety observation allows FDA to investigate possible risks without overstating what the available information demonstrates.
Analysts review information recorded in FAERS to identify patterns that may represent potential safety signals. A signal is a finding that warrants attention and further evaluation, rather than proof of a product-related risk. FDA can then examine the pattern with clinical studies and other evidence to determine whether additional action is appropriate.
Health professionals, patients, and manufacturers contribute reports through FDA programs such as MedWatch. Including these sources broadens the information available for monitoring approved drugs and biological products, while the reports still require careful evaluation because they may be incomplete and do not independently establish causation. Their combined information can help reveal patterns needing follow-up.
Reports submitted through programs such as MedWatch are recorded in FAERS, creating a body of information for FDA safety analysis. Analysts evaluate the recorded reports for patterns and possible signals. The system therefore connects initial observations from reporters with structured surveillance and subsequent review, rather than treating submission itself as a final safety conclusion.
Potential signals may prompt follow-up investigations when the reported pattern merits closer examination. Depending on what those investigations and other evidence show, FDA may pursue labeling changes, issue safety communications, request or support recalls, or make broader risk-management decisions. Reporting supplies an early basis for these steps, but the response depends on the total evidence.
In clinical settings, adverse event reports add post-approval safety information to evidence from clinical studies and other sources. This combination helps FDA assess whether an observed pattern deserves additional investigation and how risks should be managed. The process is especially relevant after products are approved, when ongoing monitoring can inform communications, labeling, recalls, or other decisions.